Clinical forecasting is now leveraging innovative informatics capabilities for more precise recruitment and endpoint projections during a study’s crucial…

Johnson & Johnson

UPDATED: J&J hikes forecast as standouts Imbruvica, Xarelto crank up pharma growth

Jury smacks J&J with $70M in damages in latest Risperdal breast case

Newest Imbruvica 'breakthrough' tag gives J&J, AbbVie hope for expansion outside blood cancers

J&J's Invokana shines in PhII Type 1 diabetes study--but raises the risk of serious side effects, too

What's the buzz at ADA? Here's your rundown, with Merck, Pfizer, Sanofi, Novo and more

In proof-of-concept trial, J&J's Invokana combo helps non-diabetics shed significant weight

Money managers pick lawsuit-besieged J&J as most respected brand in annual Barron’s poll

J&J's Darzalex slashes risk of myeloma progression by more than 60%

NICE invites angry J&J to make a Cancer Drugs Fund case for Imbruvica

Big Pharma steps up fight to defeat California drug pricing proposal